Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results

Neoplasma

Volumn 57, Issue 4, 2010, Pages 349-354

  Molnar, Z ^a   Simon, Z ^b   Borbenyi, Z ^c   Deak, B ^a   Galuska, L ^b   Keresztes, K ^b   Miltenyi, Z ^b   Marton, I ^c   Rosta, A ^a   Schneider, T ^a   Tron, L ^b   Varady, E ^a   Illes, A ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

FDG PET; Hodgkin lymphoma; Long term follow up; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; CANCER DIAGNOSIS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; EVENT FREE SURVIVAL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PROGNOSIS; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ARTICLE; COHORT ANALYSIS; EVALUATION; LABORATORY DIAGNOSIS; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955301136     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_04_349     Document Type: Review

References (25)

1. CANELLOS GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-933.
2. MAINOLFI C, MAUREA S, VARRELLA P, ALAIA C, IMPARATO C, et al.: [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]. Radiol Med (Torino) 1998; 95: 98-104.
3. NAUMANN R, VAIC A, BEUTHIEN-BAUMANN B, BREDOW J, KROPP J, et al.: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800. doi:10.1046/ j.1365-2141.2001.03147.x
4. CREMERIUS U, FABRY U, KRÖLL U, ZIMNY M, NEUERBURG J, et al.: Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients. Nuklearmedizin 1999; 38(1): 24-30.
5. DE WIT M, BOHUSLAVIZKI KH, BUCHERT R, BUMANN D, CLAUSEN M, et al.: 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37. doi:10.1023/A:1008357126404
6. JERUSALEM G, BEGUIN Y, FASSOTTE MF, NAJJAR F, PAULUS P, et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's Disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
7. HARRIS NL, JAFFE ES, STEIN H, BANKS PM, CHANG JK, et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-92.
8. HARRIS NL, JAFFE ES, DIEBOLD J, FLANDRIN G, MULLER-HERMELINK HK, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-49, 1999.
9. LISTER TA, CROWTHER D, SUTCLIFFE SB, GLATSTEIN E, CANELLOS GP, et al: Report of a committee convend to discuss the evulation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 1989, 7, 1630-36.
10. SCHULTE M, BRECHT-KRAUSS D, HEYMER B, GUHLMANN A, HARTWIG E, et al.: Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999; 26: 599-605. doi:10.1007/s002590050427
11. ROYAL HD AND MC NEIL BJ: Evaluation and impact of diagnostic tests. In: Diagnostic Nuclear Medicine. Sandler MP, Coleman RE, Wackers FJ, Patton JA, Gottshalk A and Hoffer PB (eds.) 3rd edition, Williams and Wilkins, Baltimore, pp183-198, 1996.
12. ISRAEL O, FRONT D, LAM M, BEN-HAIM S, KLEINHAUS U, et al: Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer. 1988; 61: 2439-2443. doi:10.1002/1097-0142 (19880615)61:12<2439::AID-CNCR2820611208>3.0.CO;2-Q
13. PAUL R: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987; 28: 288-292.
14. ZIJLSTRA JM, LINDAUER-VAN DER WERF G, HOEKSTRA OS, HOOFT L, RIPHAGEN II, et al.: 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91(4): 522-529.
15. BARKHEET SM, POWE J: Benign causes of 18-FDG uptake on whole-body imaging. Semin Nucl Med 1998; 28: 352-358. doi:10.1016/S0001-2998(98)80038-X
16. COOK GJR, FOGELMAN I, MAISEY M: Normal physiology and benign pathology variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: Potential for error in interpretation. Semin Nucl Med 1996; 24: 308-314. doi:10.1016/S0001-2998(96)80006-7
17. SCHAEFER NG, TAVERNA C, STROBEL K, WASTL C, KURRER M, et al.: Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed? Radiology, 2007; 244(1): 257-262. doi:10.1148/ radiol.2441060810
18. DITTMANN H, SOKLER M, KOLLMANNSBERGER C, DOHMEN BM, BAUMANN C, et al.: Comparison of 18 FDGPET with CT scans int he evaluation of patients wit residual end recurrent Hodgkin's lymphoma. Oncol Rep 2001; 8(6): 1393-1399.
19. SPAEPEN K, STROOBANTS S, DUPONT P, VAN STEENWEGHEN S, THOMAS J, et al.: Can positron emisson tomography with [(18)F]-fluorodeoxyglucose after firstline treatment distinguish between Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115(2): 272-278. doi:10.1046/j.1365-2141.2001.03169.x
20. WEIHRAUCH MR, RE D, SCHEIDHAUER K, ANSÉN S, DIETLEIN M, et al.: Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934. doi:10.1182/blood.V98.10.2930
21. GUAY C, LEPINE M, VERREAULT J, BÉNARD F: Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225-1231.
22. FRIEDBERG JW, FISCHMAN A, NEUBERG D, KIM H, TAKVORIAN T, et al: FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45: 85-92. doi:10.1080/1042819031000149430
23. PANIZO C, PEREZ-SALAZAR M, BENDANDI M, RODRÍGUEZ-CALVILLO M, BOÁN JF, et al.: Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 2004; 45: 1829-1833. doi:10.1080/1042819042000223813
24. KOBE C, DIETLEIN M, FRANKLIN J, MARKOVA J, LOHRI A, et al.: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; DOI: 10.1182/blood-2008-06-155820 doi:10.1182/blood-2008-06-155820
25. CHESON B, PFISTNER B, JUWEID M, GASCOYNE RD, SPECHT L, et al: Revised response criteria for malignant lymphoma. J of Clin Oncol 2007; 25(5): 579-586. doi:10.1200/ JCO.2006.09.2403